BioCentury | Jan 1, 2021
Targets & Mechanisms

A snapshot of target innovation in 2020

Preclinical publications highlighted in BioCentury’s Distillery this year identified white space target opportunities including untapped E3 ubiquitin ligases, vesicular regulators and ion channels, as...
BioCentury | Jun 26, 2020
Distillery Therapeutics

FMR1 peptide therapy for Fragile X syndrome

DISEASE CATEGORY: Neurology INDICATION: Fragile X syndrome An FMR1-based peptide therapy could treat Fragile X syndrome. The therapy comprises a FMR1 N-terminal fragment -- the first 297 residues -- conjugated to a cell-penetrating peptide derived...
BioCentury | Jun 26, 2020
Distillery Therapeutics

Promoting Golgi fragmentation to treat pancreatic cancer

DISEASE CATEGORY: Cancer INDICATION: Pancreatic cancer Inducing Golgi complex fragmentation by inhibiting the transcription factor KLF7 or the Golgi integrity maintenance factors DLG3 or STX5 could treat pancreatic ductal adenocarcinoma (PDAC). In pancreas samples from...
BioCentury | Mar 7, 2020
Product Development

If NoNO’s stroke trial strategy pays off, it could bring the first new therapy in a generation

Building on decades of work on a new mechanism, NoNO Inc. is laying the groundwork for an FDA approval in stroke, a notoriously difficult indication that hasn’t seen a new therapy in almost 25 years....
BioCentury | Feb 1, 2018
Translation in Brief

New Therapeutic Targets and Biomarkers: January 2018

New Therapeutic Targets and Biomarkers: January 2018 Select top therapeutic targets and biomarkers covered by BioCentury or added to the BCIQ database during January 2018. Therapeutic targets are defined as any protein, gene or other...
BioCentury | Jan 31, 2018
Distillery Therapeutics


INDICATION: Stroke Patient sample and mouse studies suggest inhibiting miR-143 or promoting expression of its inhibitor DLGAP4’s circular RNA (circRNA) could help treat stroke. In serum samples from patients, levels of miR-143 were higher and...
BioCentury | May 24, 2017
Distillery Techniques


...tumors, including a fusion between BRAF and discs large homolog-associated protein 5 ( DLGAP5 ; DLG1 ; DLG7 ; HURP...
...Medical Center Utrecht, Utrecht, the Netherlands email: Hongjiang Li University Medical Center Utrecht BRAF Discs large homolog-associated protein 5 (DLGAP5) (DLG1) (DLG7) (HURP) ES...
BioCentury | Mar 3, 2017
Clinical News

NA-1: Ph III ESCAPE-NA-1 started

NoNo began the double-blind, placebo-controlled, international Phase III ESCAPE-NA-1 trial to evaluate 2.6 mg/kg IV NA-1 in about 1,120 patients who are candidates for endovascular revascularization. NoNo Inc. , Toronto, Ontario Product: NA-1 Business: Neurology Molecular...
BioCentury | Mar 3, 2016
Targets & Mechanisms

Rescue mission

A pair of preclinical studies published last month on the autism target SHANK3 provide what might be the most meaningful progress for patients since the gene was linked with the disease over a decade ago....
BioCentury | Jan 20, 2014
Emerging Company Profile

Zocere: Stepping up in stroke

Zocere Inc. may have found a new way to decrease ischemic brain injury in patients following stroke. The company is developing an injectable, degradation-resistant version of the neuroprotective STEP protein that could improve patient outcomes...
Items per page:
1 - 10 of 19